Catalyst
Slingshot members are tracking this event:
Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PFE |
|
|
||||
Additional Information
The detailed results from the Pivotal Phase 3 studies (AD-301 and AD-302) showed that crisaborole achieved statistically significant results on primary and secondary endpoints for the treatment of atopic dermatitis (AD) in children two years of age and up and adults versus vehicle ointment alone. Crisaborole treatment-related adverse events were infrequent, mild to moderate in severity, and similar to vehicle ointment.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 13, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Crisaborole Topical Ointment, Atopical Dermatitis, An2728
